Trial Profile
A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2010
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms METABOLIC
- Sponsors Bayer
- 26 Jan 2010 Actual number of patients (5448) added as reported by ClinicalTrials.gov record.
- 26 Jan 2010 Actual number of patients (5448) added as reported by ClinicalTrials.gov record.
- 26 Jan 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov record.